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Abstract
A high-throughput prioritization method was developed for use with a validated confirmatory 
method detecting organophosphorus nerve agent exposure by immunomagnetic separation-HPLC-
MS/MS. A ballistic gradient was incorporated into this analytical method in order to profile 
unadducted butyrylcholinesterase (BChE) in clinical samples. With Zhang, et al. 1999’s Z′-factor 
of 0.88 ± 0.01 (SD) of control analytes and Z-factor of 0.25 ± 0.06 (SD) of serum samples, the 
assay is rated an “excellent assay” for the synthetic peptide controls used and a “double assay” 
when used to prioritize clinical samples. Hits, defined as samples containing BChE Ser-198 
adducts or no BChE present, were analyzed in a confirmatory method for identification and 
quantitation of the BChE adduct, if present. The ability to prioritize samples by highest exposure 
for confirmatory analysis is of particular importance in an exposure to cholinesterase inhibitors 
such as organophosphorus nerve agents where a large number of clinical samples may be 
collected. In an initial blind screen, 67 out of 70 samples were accurately identified giving an 
assay accuracy of 96% and yielded no false negatives. The method is the first to provide a high-
throughput prioritization assay for profiling adduction of Ser-198 BChE in clinical samples.
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Introduction
Cholinesterases are a family of enzymes comprised of acetylcholinesterase and 
pseudocholinesterase, also known as butyrylcholinesterase (BChE).1,2 These enzymes are 
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responsible for triggering hydrolysis of the neurotransmitter acetylcholine.3,4 Hydrolysis of 
acetylcholine follows nerve stimulation and allows the activated neuron to return to its 
resting state. Inhibitory compounds like organophosphorous nerve agents can block this 
process by binding to the cholinesterase serine active site causing a buildup of 
acetylcholine.4,5 This in turn causes the neuron to remain stimulated, sending repeated nerve 
impulses and leading to constant neuromuscular contraction. In this state, the nervous 
system is suppressed and patients experience a variety of symptoms related to cholinergic 
inhibition.5
When patients exhibit symptoms of cholinergic inhibition, their cholinesterase activity levels 
are quickly screened so that treatment, if needed, can be administered immediately. Initial 
screens of activity are effective for fast diagnoses but lack the specificity needed to identify 
and confirm the chemical agent of exposure.4 Confirmatory methods undergo formal 
validation and are reviewed annually within a quality assessment system. The methods to 
detect organophosphate exposure range from GC-MS6 and MALDI-TOF-MS7 to HPLC-
MS/MS.7–11 For each of these methods, the time-to-first-result can vary due to availability 
of reference materials, the number of analytes monitored and the complexity of the sample 
matrix. These limiting factors can be further affected by the number of samples received for 
analysis.
While confirmatory methods ensure high quality analyses for all samples, little discussion 
on prioritizing those samples has been available until recently.12 By profiling a validated 
method analyte known to be affected by exposure, analysts can organize samples so that 
those suspected of highest exposure are analyzed first. The following HPLC-MS/MS 
analysis using a ballistic gradient is designed to complement the validated confirmatory 
method currently in use. This high-throughput assay is used to profile BChE Ser-198 
adduction8,10 in serum samples and consequently, provide an effective first tier tool for 
prioritizing samples for further analysis.
Materials and Methods
Materials
Synthetic unlabeled and stable isotopically-labeled BChE peptides (FGESAGAAS and 13C9-
FGESAGAAS, respectively) of ≥90% purity were obtained from TNO (The Netherlands). 
BChE monoclonal antibodies from clone 3E8 were commercially available from 
ThermoFisher Affinity Bioreagents (Rockford, IL, USA). HPLC grade solvents acetonitrile 
and deionized water were purchased from Tedia (Fairfield, OH, USA). Formic acid (98%), 
phosphate buffered saline with Tween 20 (PBST) dry powder, dimethyl pimelimidate 
dihydrochloride (DMP), 0.2 M Tris buffered saline (TBS) 10X concentrate, triethanolamine 
buffer solution and pepsin from porcine gastric mucosa were all ordered from Sigma Aldrich 
(St. Louis, MO, USA). Dynabeads protein G were purchased from Life Technologies 
(Carlsbad, CA, USA). KingFisher 96 Flex microplates (200 μL), KingFisher 96 tip combs 
for deep well magnets, KingFisher Flex microtiter deepwell 96 plates (v-bottom), protein 
precipitation plates, 96-well PCR plates (ABgene product), PCR foil and easy pierce 20 μm 
heat sealing foil were all obtained from Fisher Scientific (Rockford, IL, USA).
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Samples were processed as previously described and recently modified.9,10 Briefly, 125 μL 
of each serum sample was pipetted into a multiscreen HTS HV 0.45 μm opaque filter plate, 
sealed with adhesive PCR foil, and centrifuged at 3,000 × g for 5 minutes at 20 °C to remove 
any fibrous tissue. A 75 μL aliquot of the filtered serum was transferred to a 96-well 
KingFisher deep well plate. A 50 μL aliquot of prepared BChE antibody-coated magnetic 
beads was placed into all wells of a 96-well KingFisher shallow well plate that corresponded 
to serum-containing wells. A ThermoScientific KingFisher Flex magnetic particle processor 
was used to transfer the BChE antibody-coated magnetic beads to the wells containing 
serum. BChE protein was allowed to bind to the antibody beads by shaking with an 
Eppendorf MixMate at 1,400 rpm for 2 hours at room temperature. The protein bound beads 
were transferred using the KingFisher to a plate containing pepsin for protein digestion. The 
pepsin plate contained 10 μL of 850 ppb internal standard (isotopically labeled synthetic 
unadducted BChE peptide (13C9-FGESAGAAS) and 75 μL 0.6% formic acid. The digestion 
plate was heated at 37 °C for 30 minutes on an Eppendorf Thermoshaker mixing at 1000 
rpm for 10 seconds per minute. The beads were removed from the sample following 
digestion using the KingFisher Flex. A 285 μL aliquot of acetonitrile was added to a Pierce 2 
mL protein precipitation plate, 0.2 μm filter. The samples from the digestion plate were then 
transferred by manual pipetting. The samples were filtered through the protein precipitation 
plate using a vacuum manifold, eluting into a 2 mL 96-well Nunc plate. The samples were 
dried to completeness under nitrogen pressure using a TurboVap at 70 °C. The samples were 
resuspended in 75 μL of 0.6% formic acid and transferred to a 96-well PCR plate. The plate 
was heat sealed with foil for HPLC-MS/MS analysis.
Preparation of stock solutions
Quality control (QC) pooled human serum was obtained from Battelle Memorial Institute 
(Columbus, OH, USA) and characterized for use.9,10 QCs were used to set the threshold for 
the prioritization method. The QC materials consisted of unexposed serum and VX exposed 
serum.
HPLC-MS/MS
BChE levels in human serum were determined on an AB Sciex 6500 triple quadrupole mass 
spectrometer (AB Sciex, Framingham, MA, USA). The instrument was tuned and calibrated 
monthly over a mass range of m/z 118–2720 using an Agilent ESI tuning mixture (P/N 
G2421A) and manufacturer autotune procedure. HPLC elution was performed using an 
Agilent 1290 Infinity series HPLC system (Agilent, Santa Clara, CA, USA). Samples (2 μL) 
were injected onto a Waters Acquity UPLC BEH C18 VanGuard PreColumn (2.1 × 5 mm, 
1.7 μm) (Waters, Milford, MA, USA). PreColumn and autosampler temperatures were 25 °C 
and 10 °C, respectively. Mobile phases were 0.1% formic acid in (A) water/acetonitrile 
(99.9:0.1) and in (B) water/acetonitrile (0.1:99.9). The following ballistic gradient 
conditions were used at a constant 250 μL flow rate and average back pressure of 143 bar: 0 
min 0%B; 0–0.01 min linear gradient 100%B; 0.01–0.35 min 100%B; 0.35–0.36 min linear 
gradient 0%B; 0.36–0.50 min 0%B. The following optimized instrument parameters were 
applied for the detection of the unlabeled analyte and the isotopically-labeled internal 
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standard: collision gas = 12 psig; curtain gas = 10 psig; ion source gas 1 = 40 psig; ion 
source gas 2 = 60 psig; ion spray voltage = 5500 V; temperature = 500 °C; collision exit 
potential = 20 V; declustering potential = 136 V; entrance potential = 10 V; dwell time = 35 
ms; 5.0 mm vertical probe height and a ‘unit’ resolution of 0.7 amu at full width half max. 
Detection of the BChE pepsin digest product peptide FGESAGAAS was determined by 
selected reaction monitoring (SRM) (BChE detection ion m/z 796.3 → 691.3, collision 
energy = 34 V; confirmation ion m/z 796.3 → 620.3, collision energy = 36 V and 13C9-
BChE internal standard m/z 805.4 → 700.3, collision energy = 34 V) in ESI positive ion 
mode.
Data acquisition and processing
Crystal structures were produced using PyMOL v. 1.5 from Schrödinger LLC (Portland, OR, 
USA). Data acquisition and spectral analysis were carried out utilizing AB Sciex Analyst v.
1.6 build 6536. The capacity factor for the separation was calculated by k′=(tr−tm)/tm, where 
tr is the analyte retention time and tm is the system void volume. Zhang, et al. 1999’s Z-
factor of the 96-well plate assay was calculated as Z=1−((3σs + 3σc)/|μs − μc|), where σ is 
the standard deviation, μ is the mean, c is the control, s is the sample and abs is the absolute 
value.13 Similarly, the Z′-factor was calculated.13 Percent relative standard deviation 
%RSD=(SD/Cavg)×100 was calculated as a measure of assay precision, where Cavg is the 
average concentration calculated, and SD is the standard deviation of Cavg. Intraplate 
precision was determined with an analyte n≥48 and interplate accuracy was determined with 
a plate n=3. Assay accuracy was calculated as %Accuracy= (ncorr/ntotal) × 100, where ncorr 
are the number of samples prioritized correctly and ntotal are the number of samples total. 
The assay’s confirmation rate was determined as a percentage by %CR= (hits confirmed/hits 
selected) × 100, where hits are the samples found to have low unadducted BChE levels and 
thereby high priority for further analysis.
Convenience sample set
A set of 100 individual human sera samples was commercially obtained from Tennessee 
Blood Services (Memphis, TN, USA).
Results and Discussion
A novel validated method for extracting human BChE from serum or plasma by 
immunomagnetic separation coupled with isotope-dilution HPLC-MS/MS was developed by 
Sporty and colleagues in 2010.8,10 This combination of analytical techniques enabled 
analysts to obtain and quantitatively measure a direct protein biomarker of organophosphate 
exposure from clinical samples. Since BChE is functional in ≥99.9% of the general 
population,14 profiling this biomarker provides a meaningful target for prioritizing samples 
received during a potential exposure to cholinesterase inhibitors. Detection of 
organophosphate adducts to the BChE target are projected up to 55 days post-exposure, 
expanding response time by 95% from the urinary metabolite method’s three day response 
time.6,11 Although further automation of the adduct method led to more efficient sample 
processing times, sample reporting remained dependent on a 10 hr/96-well plate HPLC-
MS/MS analysis and the subsequent data review of the multi-analyte system.9 If samples 
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were prioritized before they were analyzed with the more complex confirmatory methods, 
samples with the highest exposure profiles would have a faster time-to-report. The benefits 
of this prioritization design ensure that investigators obtain information about a chemical 
emergency in the order of highest exposure first.
The key to adding a prioritization method before the confirmatory method was to not 
prolong the original time-to-first-result. The confirmatory method analysis time for initial 
calibration and QCs was 1.75 hr. A high-throughput prioritization method was designed to 
profile at least 96 unknown clinical samples in less than 1.75 hr. The desired method was 
achieved using a ballistic HPLC gradient. First termed in 2000, ballistic gradients are rapid 
gradients at high flow rates on short and narrow-bore columns.15 A 0.5 min ballistic gradient 
HPLC-MS/MS analysis was developed to target unadducted BChE peptide at a fifth of the 
confirmatory method’s sample volume (Figure 1). A BChE peak at 0.24 min was observed 
with a measured k′=3.8. Since the BChE peptide used was the same as the biomarker 
peptide extracted for the confirmatory method, the method had the additional benefit of not 
altering the original sample processing protocol.10 The method enabled BChE profiles to be 
collected from a 96-well plate in 1.6 hr and queued into the confirmatory analysis method in 
order of suspected exposure.
The analysis of the unadducted BChE in each sample included monitoring the ESI-MS/MS 
target ion transition m/z 796.3→691.3; confirmatory target ion transition m/z 796.3→620.3 
and the isotopically-labeled internal standard ion transition m/z 805.4 → 700.3. The peak 
area ratio of the target to the internal standard was used to establish assay parameters. Assay 
quality was determined using Zhang, et al. 1999’s high-throughput Z-factor parameter.13 A 
checkerboard 96-well plate of alternating unadducted and adducted synthetic BChE peptide 
standards were used to assess the developed method’s ability to discriminate between 
unadducted BChE target and adducted BChE (Figure 2A). The peptide standards were 
prepared at 37 ng/mL, equivalent to the QC material concentration measured in the 
confirmatory method. Only baseline detection of adducted BChE synthetic standards was 
observed due to the high specificity of MS/MS analysis. The calculated Z′-factor was 0.88 
± 0.01 (SD) and described an “excellent assay” capable of distinguishing the target with 
confidence.13 The high precision of the peptide standard was 4 %RSD intraplate (n=48) and 
7 %RSD interplate (n=3). A naturally lower Z-factor was predicted and observed for matrix 
serum targets from clinical samples (Figure 2B). The calculated Z-factor for serum QC 
reference material was found to be 0.25 ± 0.06 (SD) and termed a “double assay”.13 This 
classification was as intended since the profiling method was designed as a means of 
prioritization before the validated confirmatory method. Profiles of unadducted BChE 
extracted from the unexposed QC reference material were found to be less precise than the 
synthetic standards but still within a high working range of 13 %RSD intraplate (n=48) and 
15 %RSD interplate (n=3).
A high confidence in the initial assay quality was established, and a commercial convenience 
set of individual human serum samples were tested. The BChE target peptide was observed 
in all of the 96 individual samples with an average response not unlike that observed in the 
serum QC reference materials (Figure 2C). An intraplate precision of 19 %RSD was 
calculated among the individual samples and was used to set the threshold for the assay. A 
Carter et al. Page 5





















threshold of 19 % of the mean was representative of the reported 22 % population 
variability.5 Samples with a response lower than one standard deviation of the mean 
(equivalent to 19 %RSD) would be classified as “hits” or high priority samples in the 
confirmatory analysis queue. The authors understand a threshold at one standard deviation of 
the mean will return an abnormally high number of false positives due to the inherent target 
BChE variability in the general population, but this low threshold will also reduce, if not 
eliminate, the number of false negatives observed. The importance of avoiding false 
negatives in a chemical emergency or exposure sample set is of utmost importance for 
formal investigation purposes.
The final prioritization method parameters were applied to a blind response sample set. A 
blinded plate containing 70 potential exposure samples was prepared and profiled for 
priority of suspected organophosphate exposure. Samples were comprised of an array of QC 
materials and individual serum samples. Of the 70 samples analyzed, 67 samples were 
classified correctly giving a high assay accuracy of 96%. The confirmation rate of the 
identifications was also high at 93% which means that of the 45 hits prioritized, 42 were 
later confirmed (Figure 3). The three unconfirmed hits were labeled false positives; no false 
negatives were observed. A tested assay threshold that did not return false negatives is 
extremely important when coupled to a confirmatory method for organophosphate exposure.
The described high-throughput prioritization method was developed for use with a validated 
confirmatory method detecting organophosphate exposure by immunomagnetic separation-
HPLC-MS/MS. While all potential exposure samples received would be analyzed with equal 
care using a validated confirmatory method, sample profiles with suspected 
organophosphate exposure would be queued for analysis first. A prioritization assay 
accuracy of 96% and confirmation rate of 93% illustrates the confidence with which this 
approach can be used. Prioritizing potential exposure samples therefore increases the value 
of the validated method’s time-to-first-result and will be important in organizing sample 
analyses in the case of a large scale exposure event.
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Figure 1. Human BChE was extracted by immunomagnetic separation, digested by pepsin and 
analyzed by HPLC-MS/MS analysis
The X-ray crystal structure of human BChE with waters removed for clarity was created 
using PyMOL (PDB identifier 1P0M). The Ser-198 containing BChE peptide 
(FGESAGAAS) is highlighted in black. A representative extracted ion chromatogram of the 
peptide transition m/z 796.3 → 691.3 is shown at retention time 0.24 minutes (k′=3.8).
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Figure 2. Zhang, et al. 1999’s Z-factor was used to evaluate assay quality across each 96-well 
plate
The Z-factor parameter was calculated using a checkerboard 96-well plate analysis for the 
system’s A) synthetic positive and negative controls (◆-unadducted FGESAGAAS peptide 
and ▲-VX-adducted FGESAGAAS peptide) yielding an excellent assay Z′-factor of 0.88 
± 0.01 (SD) and B) quality control reference materials (◆-human serum and ▲-fully VX-
adducted human serum) returning a double assay Z-factor of 0.25 ± 0.06 (SD). C) A 
convenience set of 96 individual serum samples (◆) were analyzed for comparison to the 
parameters of the quality control materials. The mean (solid line) and three standard 
deviations of the mean (dashed line) were calculated for all samples. One standard deviation 
of the mean (dotted line) was set as the assay threshold. Below the threshold, samples were 
considered high priority or “hits”.
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Figure 3. The assay was used to prioritize samples from a blind response exercise
The assay was shown to have an accuracy of 96%, evaluating 67 of the 70 samples as 
expected. There were 42 known hits of high priority (▲) in the sample set; the 42 hits were 
confirmed plus three false positives (x) and no false negatives, giving a high confirmation 
rate of 93%. All other samples (◆) are distributed around the mean. The mean (solid line), 
three standard deviations of the mean (dashed line) and one standard deviation of the mean 
(dotted line) were the parameters established from the individual serum convenience set.
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